Swiss Atrial Fibrillation Pulmonary Vein Isolation Registry

Overview

Registry of patients with atrial fibrillation undergoing catheter-based ablation of atrial fibrillation (pulmonary vein isolation) to determine long-term success rates of catheter-based ablation of atrial fibrillation (pulmonary vein isolation) and to evaluate factors associated with long-term success of catheter-based ablation of atrial fibrillation (pulmonary vein isolation).

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2035

Interventions

  • Procedure: catheter-based ablation of atrial fibrillation (pulmonary vein isolation)
    • catheter-based ablation of atrial fibrillation (pulmonary vein isolation)

Clinical Trial Outcome Measures

Primary Measures

  • changes in retention rate of normal sinus rhythm after catheter-based ablation of atrial fibrillation (pulmonary vein isolation)
    • Time Frame: before catheter-based ablation of atrial fibrillation and 3, 6 and 12 months after catheter-based ablation of atrial fibrillation
    • changes in retention rate of normal sinus rhythm after catheter-based ablation of atrial fibrillation (pulmonary vein isolation)

Secondary Measures

  • morphologic changes of left cardiac atrium
    • Time Frame: before catheter-based ablation of atrial fibrillation (pulmonary vein isolation)
    • echocardiography of left cardiac atrium
  • changes in retention rate of normal sinus rhythm after catheter-based ablation of atrial fibrillation (pulmonary vein isolation)
    • Time Frame: 12 months after catheter-based ablation of atrial fibrillation and then at intervals of one year until 2035
    • changes in retention rate of normal sinus rhythm after catheter-based ablation of atrial fibrillation (pulmonary vein isolation)

Participating in This Clinical Trial

Inclusion Criteria

  • patients undergoing catheter-based ablation of atrial fibrillation (pulmonary vein isolation)

Exclusion Criteria

  • Patients not able or willing to participate in this study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Basel, Switzerland
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Michael Kuehne, MD, Principal Investigator, Cardiology/Electrophysiology, University Hospital Basel
  • Overall Contact(s)
    • Michael Kuehne, MD, +41 61 328 74 71, michael.kuehne@usb.ch

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.